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6 Università La Sapienza, Policlinico Umberto I, Roma, Italy; 7 Ospedale Niguarda, Milano, Italy; 8 ULSS12 Venezia, Venezia, Italy; 9 Wyeth, Aprilia, Aprilia, Italy OBJECTIVE: Rheumatoid Arthritis (RA) is a disease with high socioeconomic impact. Anti-TNF drugs have provided evidence of effectiveness in treating RA patients resistant to 2 previous conventional DMARDs, including MTX, as demonstrated by a number-needed-to-treat (NNT) of 2 to produce a 20% improvement in American College of Rheumatology (ACR) score (ACR20). Anti-TNF therapy is also costly. The aim of this retrospective longitudinal cost of care analysis was to evaluate the cost of Etanercept (ETA) vs Infliximab (IFX) used at the standard dosage (according to the ANTARES Protocol) for the treatment of RA patients after DMARDs (disease-modifying anti-rheumatic drugs) failure in Italy. METHODS: The study included subjects randomly enrolled from 7 centres participating to a prospective data collection program called ANTARES. Direct health care resources attributable to RA management (drugs, ambulatory care, day case treatments, hospitalizations) were quantified using National Health Service (NHS) tariffs expressed in Euro 2003. NHS perspective was adopted. Multiple linear regression techniques were used to investigate differences between IFX and ETA in the direct cost, adjusting for sex, age, baseline ESR (erythrocyte sedimentation rate), baseline DAS (disease activity score) and centre. RESULTS: A total of 211 (IFX 101, ETA 110) patients affected by RA (F/M 165/46; mean age 50.7 ± 14.5 years old) were studied. Mean total annual direct costs for RA patients were euro 16,988 (±7245). The regression analysis showed that adjusting for sex, baseline ESR, age, baseline DAS and centres total direct costs per patient in ETA group were 3427 Euro lower than in IFX patients (P < 0.0001). CON-CLUSIONS: The total direct cost of Etanercept is statistically significantly lower than Infliximab, when the drug are used at the standard dosage, according to the ANTARES Protocol.
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OBJECTIVES:
The aim was to focus on the financial burden of co-payments for patients with rheumatoid arthritis under new German law regulations. METHODS: The assessment of all cost data was part of a clinical multicenter randomized RA-trial in Germany. For 136 RA-patients (1987 ACR criteria, mean age 57.4 (±12.5) years, mean disease duration 8.2 (±8.4) years, 77% females) every 3 months corresponding cost data were derived from 1) a RA-related patient-centered health economic questionnaire, and 2) the payer's database (insurance and physicians' association) over a period of 18 months. Co-payments in Germany partly can be derived by analyzing the payers' data due to specific legal regulations. In addition to that patient-derived data was evaluated. RESULTS: The data was composed in a matrix of different cost domains. Those led to patient copayments/ year of 417.10€. Visits to a physician accounted for 9.2% (38.40€), non-physician service utilization for 46.6% (194.40€), medication for 23.7% (99€), hospital co-payments for 5.8% (24€), transportation for 13.5% (56.20€), and devices and aids for 1.2% (5.10€) of the overall co-payment costs. CON-CLUSIONS: The impact of co-payments on patients with chronic diseases needs to be addressed by policy makers. Even in an environment with relatively low co-payment regulations like Germany the burden for RA-patients can become substantial. 3 Pfizer SA, Alcobendas, Madrid, Spain OBJETIVES: ARTS is a self reported instrument designed to measure four treatment satisfaction dimensions: Treatment advantages, Treatment convenience, Apprehension about treatment and Satisfaction with medical care; and is composed by 18 Likert-scale items. It is intended to be used with patients suffering osteoarthritis and undergoing oral administered treatments. METHODS: Linguistic adaptation was performed using the standard processes for establishing conceptual equivalence. A panel of six experts supervised the process and four independent translators translated and back-translated the items. A sample of 163 patients was used to gauge psychometric properties. All patients suffered from knee, hip or column arthritis. Patients were included in 3 groups: treatment-switch because of a weak analgesic effect, treatment-switch due to poor tolerability and no-change. The ARTS was administered at baseline, 1 week later and after 4 weeks of therapy with traditional NSAIDs or Cox IIinhibitors. RESULTS: Mean age was 67.7 ± 9.2 years old. The adapted instrument showed good feasibility and reliability properties. No floor or ceiling effects where found, items where well understood and non-response rates were below one percent (1%). Cronbach's alpha for the total scales was 0.85. Instrument was stable with a test-retest intraclass correlation coefficient of 0.83. Exploratory factor analysis yielded four dimensions coherent with those proposed by the original authors. Convergent validity was measured against SF-36, a pain VAS a treatment compliance VAS, and Morisky-Green compliance questionnaire. The adapted instrument showed good discriminant validity, being able to distinguish between patients needing a change in
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